Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALDX Stock Forecast 2026-2027
$1.72
Current Price
$116.42M
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ALDX Price Targets
+655.8%
To High Target of $13.00
+307.0%
To Median Target of $7.00
+16.3%
To Low Target of $2.00
ALDX Price Momentum
-16.9%
1 Week Change
-6.0%
1 Month Change
-65.8%
1 Year Change
-66.8%
Year-to-Date Change
-72.1%
From 52W High of $6.18
+60.7%
From 52W Low of $1.07
📊 TOP ANALYST CALLS
Did ALDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aldeyra is one of their latest high-conviction picks.
Latest ALDX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ALDX has a bullish consensus with a median price target of $7.00 (ranging from $2.00 to $13.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.72, the median forecast implies a 307.0% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 16.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALDX Analyst Ratings
5
Buy
1
Hold
0
Sell
ALDX Price Target Range
Low
$2.00
Average
$7.00
High
$13.00
Current: $1.72
Latest ALDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2026 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $2.00 |
| Nov 10, 2025 | BTIG | Buy | Reiterates | $N/A | |
| May 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 7, 2025 | BTIG | Buy | Maintains | $N/A | |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 9, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 2, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 6, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| May 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 3, 2024 | Oppenheimer | Outperform | Upgrade | $N/A | |
| Apr 2, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reinstates | $10.00 |
| Oct 17, 2023 | Citigroup | Buy | Maintains | $N/A | |
| Oct 17, 2023 | Oppenheimer | Perform | Downgrade | $N/A | |
| Aug 9, 2023 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Jun 30, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 22, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 16, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 2, 2023 | Citigroup | Buy | Maintains | $N/A | |
| Jun 1, 2023 | Citigroup | Buy | Maintains | $N/A |
Aldeyra Therapeutics Inc. (ALDX) Competitors
The following stocks are similar to Aldeyra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aldeyra Therapeutics Inc. (ALDX) Financial Data
Aldeyra Therapeutics Inc. has a market capitalization of $116.42M with a P/E ratio of -3.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -51.8%.
Valuation Metrics
Market Cap
$116.42M
Enterprise Value
$66.93M
P/E Ratio
-3.5x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+62.7%
Current Ratio
2.7x
Debt/Equity
36.8x
ROE
-51.8%
ROA
-22.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aldeyra Therapeutics Inc. (ALDX) Business Model
About Aldeyra Therapeutics Inc.
What They Do
Develops therapies for immune-mediated and metabolic diseases.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on the discovery and development of therapies targeting immune-mediated and metabolic diseases. It generates revenue through the development of its proprietary product candidates, including reproxalap for dry eye disease and ADX-2191 for rare retinal conditions, which are in various stages of regulatory approval.
Additional Information
Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, and emphasizes a unique RASP modulator platform that aims to minimize toxicity while addressing complex biological pathways. The company has received orphan drug and fast track designations for some of its products, indicating its commitment to developing innovative treatments for underserved medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. Todd C. Brady M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.aldeyra.comAldeyra Therapeutics Inc. (ALDX) Latest News & Analysis
Latest News
Levicept Appoints Darlene Deptula-Hicks as CFO
10 days ago
Quick Summary
A US-based public markets leader has joined a company advancing late-stage development of LEVI-04 for osteoarthritis, indicating progress in their product pipeline.
Why It Matters
The addition of an experienced leader signals confidence in the company's strategy and enhances its capability to advance LEVI-04, potentially boosting future revenues and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aldeyra Therapeutics appointed Darlene Deptula-Hicks to its board of directors. She has extensive experience in biotechnology firms, enhancing the company's leadership.
Why It Matters
The appointment of Darlene Deptula-Hicks to Aldeyra's board enhances leadership credibility and may positively influence strategic decisions, impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Aldeyra Therapeutics (NASDAQ: ALDX) anticipates feedback from the FDA on its dry eye disease candidate reproxalap, following a third complete response letter regarding efficacy.
Why It Matters
FDA feedback on reproxalap could determine Aldeyra's market trajectory. Positive news may boost stock prices, while continued regulatory hurdles could lead to declines.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Aldeyra Therapeutics' CEO, Dr. Todd C. Brady, will speak at the 2026 Jefferies Global Healthcare Conference in New York, highlighting the company's focus on therapies for immune-mediated diseases.
Why It Matters
Aldeyra Therapeutics’ CEO speaking at a major healthcare conference highlights company visibility and potential investor interest, impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi, LLP is investigating potential claims against Aldeyra Therapeutics (NASDAQ: ALDX) and reminds investors of a May 29, 2026 deadline to join a federal securities class action.
Why It Matters
Aldeyra Therapeutics faces potential legal claims, which could impact its stock price and investor confidence. The class action deadline adds urgency for those affected.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ALDX investors can lead a securities fraud lawsuit against Aldeyra Therapeutics, Inc. with the Schall Law Firm, as announced in a recent business update.
Why It Matters
A securities fraud lawsuit could impact Aldeyra Therapeutics' stock price and investor confidence, potentially leading to volatility and financial repercussions for shareholders.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ALDX Stock
What is Aldeyra Therapeutics Inc.'s (ALDX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Aldeyra Therapeutics Inc. (ALDX) has a median price target of $7.00. The highest price target is $13.00 and the lowest is $2.00.
Is ALDX stock a good investment in 2027?
According to current analyst ratings, ALDX has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALDX stock?
Wall Street analysts predict ALDX stock could reach $7.00 in the next 12 months. This represents a 307.0% increase from the current price of $1.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aldeyra Therapeutics Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the discovery and development of therapies targeting immune-mediated and metabolic diseases. It generates revenue through the development of its proprietary product candidates, including reproxalap for dry eye disease and ADX-2191 for rare retinal conditions, which are in various stages of regulatory approval.
What is the highest forecasted price for ALDX Aldeyra Therapeutics Inc.?
The highest price target for ALDX is $13.00 from at , which represents a 655.8% increase from the current price of $1.72.
What is the lowest forecasted price for ALDX Aldeyra Therapeutics Inc.?
The lowest price target for ALDX is $2.00 from Matthew Caufield at HC Wainwright & Co., which represents a 16.3% increase from the current price of $1.72.
What is the overall ALDX consensus from analysts for Aldeyra Therapeutics Inc.?
The overall analyst consensus for ALDX is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are ALDX stock price projections?
Stock price projections, including those for Aldeyra Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:04 AM UTC